VH4011499

DRUG4 trials

Sponsors

ViiV Healthcare

Conditions

HIV Infections

Phase 1

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

CompletedNCT05393271

ViiV HealthcareHIV Infections

Start: 2022-10-03End: 2023-04-24Updated: 2025-04-01

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

CompletedNCT06012136

ViiV HealthcareHIV Infections

Start: 2023-08-24End: 2026-06-09Updated: 2026-08-05

Phase 2

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

CompletedNCT06039579

ViiV HealthcareHIV Infections

Start: 2023-10-25End: 2024-06-24Updated: 2025-09-30

A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)

Not yet recruitingNCT07816250

ViiV HealthcareHIV Infections

Start: 2026-10-19End: 2032-06-11Target: 200Updated: 2026-09-11

Related Papers

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

2026-07-29

Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV.

2025-04-262 citations

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

Infectious Diseases and Therapy2025-04-022 citations